NextCell Pharma, a clinical-stage cell therapy company developing ProTrans, expanded its portfolio by developing a research-use-only umbilical cord MSC product in 2024, manufactured using proprietary in-house expertise for the commercial market. Building on this progress, the company is now initiating a collaboration with Fujifilm Irvine Scientific Inc. (Fujifilm) to combine this cell product with Fujifilm’s established MSC media and cryopreservation product lines.

Fujifilm is a global player in the development of high-quality cell culture solutions for the life science and medical markets. With over 50 years of industry experience, Fujifilm is recognised for its innovation and commitment to advancing areas such as cell and gene therapy.

This joint offering is expected to provide researchers and industry stakeholders with standardised, high-quality MSC reference material, optimised media and cryopreservation solutions for MSC culture and cold storage and a reliable reference system for the development and validation of new therapies.

“We have worked closely together to develop this business relationship and are proud to be able to announce this new opportunity to our shareholders,” said CSO at NextCell, Dr. Lindsay Davies.

“This is a new business venture for NextCell, and we are excited to collaborate with Fujifilm, combining our expertise to build a strong partnership for the future,” said CEO of NextCell, Mathias Svahn.